Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Trial Profile

Open Label Study of Tolerability, Pharmacokinetics and Pharmacodynamics of BCD-054 (Pegylated Interferon Beta-1a), IM and SC, Compared to Rebif® and Avonex® in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Peginterferon beta-1a (Primary) ; Peginterferon beta-1a (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Biocad
  • Most Recent Events

    • 12 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 18 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top